Scans don't show p53 activation. They also can't show growth arrest without other measures and indicators. If there is no measurable reduction, then scans show nothing at all, which is why they are taken at 2 months, 4 months and 6 months.


qPCR will accurately show any increase in p21 presence, a measurable proof of efficacy in real time. One assumes that even for low doses with each weekly dose there is a small rise, or spike, and through repetition that rise can be associated with Kevetrin, but this happens only once a threshold dose is reached that results in p53 cascade. The first and second doses seem unlikely to produce this cascade.


Also, in the absence of tumor shrinkage, escalating doses would be expected to result in a similar escalation of p21 presence. There are now two dose levels (cohorts 1and2) and possibly three (plus cohort 3) for proof of this correlation, if there is increased presence detected.

My expectation is for a minimally significant increase in p21 presence for the 3rd cohort, if it is included in the current qPCR. My hope is that the first dose showed this minimal increase, and p21 presence is confirmed with the second cohort and possibly reconfirmed and clearly increasing by the 3rd. But, this is only my hope and best case outcome, which I think is why DF is running qPCR this soon.